Tambotatug pelitecan

Phase 3

MMediLink Therapeutics (Suzhou) Co., Ltd.

Tambotatug pelitecan is one of 4 therapeutic programs targeting Metastatic Pancreatic Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Metastatic Pancreatic CancerNot yet recruiting

Metastatic Pancreatic CancerPhase 3

Not yet recruiting

Competition

Competitive Landscape

3 competitors in Metastatic Pancreatic Cancer

#DrugCompanyPhaseTrials

GFH375

GGenfleet Therapeutics (Shanghai) Inc.

Phase 3

1 2

Tambotatug pelitecan

MMediLink Therapeutics (Suzhou) Co., Ltd.

Phase 3

1 3

Ga DOTA

UUniversity of California, Davis

Phase 1

1 4

XNW28012

EEvopoint Biosciences Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 3Not yet recruiting

Metastatic Pancreatic Cancer

NCT07803783

Clinical

Trials by Indication[1]

Metastatic Pancreatic Cancer1 trial

A Randomized, Controlled, Multicenter Phase III Study to Evaluate the Efficacy and Safety of YL201 Versus Liposomal Irinotecan in Combination With 5-Fluorouracil/Leucovorin in Participants With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed Prior Gemcitabine-based Systemic Therapy

Not yet recruiting·MMediLink Therapeutics (Suzhou) Co., Ltd.·Phase 3·NCT07803783·320 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Tambotatug pelitecan. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Tambotatug pelitecan. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — MediLink Therapeutics (Suzhou) Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: MMediLink Therapeutics (Suzhou) Co., Ltd.

Tambotatug pelitecan

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Metastatic Pancreatic Cancer1 trial

References

Drug Info

Quick Facts

Related News